Please login to the form below
sunitinib
This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
In June, Merck and Eisai also announced that the Keytruda plus Lenvima combination treatment improved outcomes when compared to Pfizer’s Sutent (sunitinib) on a measure of health-related quality of ... Previously, Merck and Eisai reported that Keytruda
Latest news
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients. ... Previously, Merck and Eisai reported that Keytruda and Lenvima met the primary endpoint of improved progression-free survival (PFS)
-
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
older TKI Sutent (sunitinib) in patients with advanced RCC.
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of
-
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
sunitinib) in the first-line treatment of advanced renal cell carcinoma (RCC) – the most common type of kidney cancer in adults.
-
BMS gains FDA approval for second Opdivo combo in kidney cancer
This approval is based on results from the phase 3 CheckMate-9ER trial, which compared Opdivo plus Cabometyx to Pfizer’s older tyrosine kinase inhibitor (TKI) Sutent (sunitinib) in patients with
More from news
Approximately 2 fully matching, plus 76 partially matching documents found.
Latest appointments
-
Cipla appoints Novartis’ Subhanu Saxena as CEO
The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
-
Oncology drugs under AMNOG
Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
